Brief: Arcellx Inc Estimated Median Progression Free Survival By Kaplan-Meier Is 28 Months
08/12/2023 21:02
Dec 9 (Reuters) - Arcellx Inc ACLX.O :
* ARCELLX ANNOUNCES CONTINUED ROBUST LONG-TERM RESPONSES
FROM ITS
CART-DDBCMA (ANITO-CEL) PHASE 1 EXPANSION TRIAL IN PATIENTS WITH
RELAPSED OR REFRACTORY MULTIPLE MYELOMA AT ASH
* ARCELLX INC - ESTIMATED MEDIAN PROGRESSION FREE SURVIVAL
BY
KAPLAN-MEIER IS 28 MONTHS
Source text for Eikon: ID:nPn9GfGJla
Further company coverage: ACLX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Arcellx
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 02:18 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite